May, James
Duncan, Colin
Mol, Ben
Bhattacharya, Siladitya
Daniels, Jane
Middleton, Lee
Hewitt, Catherine
Coomarasamy, Arri
Jurkovic, Davor
Bourne, Tom
Bottomley, Cecilia
Peace-Gadsby, Alexandra
Doust, Ann
Tong, Stephen
Horne, Andrew W.
Funding for this research was provided by:
Efficacy and Mechanism Evaluation Programme (14/150/03)
Article History
Received: 24 May 2018
Accepted: 20 October 2018
First Online: 20 November 2018
Ethics approval and consent to participate
: Ethical approval was obtained from the Scotland A Research Ethics Committee (16/SS/0014) on 29 February 2016. Data will be presented at international conferences and published in peer-reviewed journals. We will make the information available to the public through national bodies and charities, e.g. the Ectopic Pregnancy Trust.
: Not applicable.
: ST holds a patent that relates to the use of gefitinib to treat ectopic pregnancies. BM is supported by a NHMRC Practitioner Fellowship (GNT1082548). BWM reports consultancy for ObsEva, Merck KGaA, and Guerbet. CB is on the advisory panel for Clearblue, was Scientific Chair of the Association of Early Pregnancy Units 2015–2017, and is a Medical Advisor to the Ectopic Pregnancy Trust. TB receives departmental research support from Roche Diagnostics and Samsung Medison. AWH is on the Scientific Board of the Association of Early Pregnancy Units, and is a Trustee and Medical Advisor to the Ectopic Pregnancy Trust. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.